²ÝÝ®ÊÓƵ College of Pharmacy’s Edward Li testifies at FDA Advisory Committee on breast cancer treatment drug
Edward Li, Pharm.D., M.P.H., BCOP, professor in the College of Pharmacy, has testified at the Open Public Hearing portion of the July 13, 2017 Oncologic Drugs Advisory Committee. The committee discussed the biologics license application of a proposed biosimilar to Herceptin® (trastuzumab), used to treat a form of breast cancer.
Biosimilars are a type of biological product that are licensed (approved) by the FDA because they are highly similar to an already FDA-approved